EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Computational structural optimization enhances IL13Rα2 – B7-H3 tandem CAR T cells to overcome antigen-heterogeneity-mediated tumor escape

Michaela M Meehl, Kalyan Immadisetty, Vikas D Trivedi, Pawel Glowacki, Brooke Prinzing, Alejandro Allo Anido, Jorge Ibañez-Vega, Benjamin J Leslie, M Madan Babu, Giedre Krenciute

Molecular Therapy · 2025

DOI: 10.1016/j.ymthe.2025.07.044 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Therapy, 2025. Verfasst von Michaela M Meehl und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Bone Marrow Transplantation and Cellular Therapy (BMTCT), St. Jude Children's Research Hospital, Memphis, TN 38105, USA; College of Gra…. Hauptthemen laut MEDLINE: Interleukin-13 Receptor alpha2 Subunit, Receptors, Chimeric Antigen, Immunotherapy, Adoptive, B7 Antigens. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 78 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCI NIH HHS, NINDS NIH HHS, Assisi Foundation of Memphis Inc.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chimeric antigen receptor (CAR) T cell therapy is a highly effective treatment for multiple malignancies. However, one limitation is tumor antigen-heterogeneity and downregulation, which allows tumor cells to evade conventional, monospecific CAR T cells. One approach to overcome this tumor escape is by utilizing a tandem CAR recognizing two antigens. However, tandem CAR constructs often require optimization to achieve cell surface expression and function. Herein, we describe our process of designing an IL-13Rα2-B7-H3 tandem CAR. Interestingly, our original tandem CAR failed to express on the cell surface, leading to a systematic evaluation of 24 tandem constructs varying in their scFv positioning, linkers, and specific amino acids. We identified a "trouble region" in the CAR and optimized it using computational approaches, rescuing surface expression and improving function compared with monospecific CAR T cells. Further, the optimized tandem CAR T cells more effectively eliminated tumors than monospecific CAR T cells in vivo. Our study demonstrates the successful application of structure-guided computational strategies to restore surface expression and antitumor efficacy of an IL13Rα2 - B7-H3 tandem CAR. Our study also highlights the necessity of computational methods to guide the design of synthetic proteins, and that these methods can increase CAR T cell efficacy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Interleukin-13 Receptor alpha2 SubunitReceptors, Chimeric AntigenImmunotherapy, AdoptiveB7 AntigensTumor EscapeT-LymphocytesNeoplasmsHumansAnimalsMiceCell Line, TumorXenograft Model Antitumor AssaysAntigens, Neoplasm

Stichwörter der Autor:innen

CAR T cellsIL13Rα2 – B7-H3antibody engineeringantigen escapecell surface expression optimizationcomputational structure predictionexpression fitness scorelinker engineeringprotein engineeringtandem bispecific CAR

Substanzen

Interleukin-13 Receptor alpha2 SubunitReceptors, Chimeric AntigenB7 AntigensCD276 protein, humanAntigens, NeoplasmIL13RA2 protein, human

Autor:innen und Institutionen

  • Department of Bone Marrow Transplantation and Cellular Therapy (BMTCT), St. Jude Children's Research Hospital, Memphis, TN 38105, USA; College of Graduate Health Sciences, University of Tennessee Health Science Center,…
  • Department of Bone Marrow Transplantation and Cellular Therapy (BMTCT), St. Jude Children's Research Hospital, Memphis, TN 38105, USA; Center of Excellence for Data Driven Discovery, St. Jude Children's Research Hospita…
  • Center of Excellence for Data Driven Discovery, St. Jude Children's Research Hospital, Memphis, TN 38105, USA; Department of Structural Biology, St. Jude Children's Research Hospital, Memphis, TN 38105, USA.
  • Department of Bone Marrow Transplantation and Cellular Therapy (BMTCT), St. Jude Children's Research Hospital, Memphis, TN 38105, USA.
  • Center of Excellence for Data Driven Discovery, St. Jude Children's Research Hospital, Memphis, TN 38105, USA; Department of Structural Biology, St. Jude Children's Research Hospital, Memphis, TN 38105, USA. Electronic…
  • Department of Bone Marrow Transplantation and Cellular Therapy (BMTCT), St. Jude Children's Research Hospital, Memphis, TN 38105, USA. Electronic address: giedre.krenciute@stjude.org.

Förderung

  • NCI NIH HHS
  • NINDS NIH HHS
  • Assisi Foundation of Memphis Inc
  • American Lebanese Syrian Associated Charities
  • National Institute of Neurological Disorders and Stroke

Zitieren

APA

Meehl, M. M., Immadisetty, K., Trivedi, V. D., Glowacki, P., Prinzing, B., Anido, A. A., Ibañez-Vega, J., Leslie, B. J., Babu, M. M., & Krenciute, G. (2025). Computational structural optimization enhances IL13Rα2 – B7-H3 tandem CAR T cells to overcome antigen-heterogeneity-mediated tumor escape. Molecular Therapy. https://doi.org/10.1016/j.ymthe.2025.07.044

Vancouver

Meehl MM, Immadisetty K, Trivedi VD, Glowacki P, Prinzing B, Anido AA, et al. Computational structural optimization enhances IL13Rα2 – B7-H3 tandem CAR T cells to overcome antigen-heterogeneity-mediated tumor escape. Molecular Therapy. 2025. doi:10.1016/j.ymthe.2025.07.044

BibTeX
@article{Meehl2025,
  author = {Meehl, Michaela M and Immadisetty, Kalyan and Trivedi, Vikas D and Glowacki, Pawel and Prinzing, Brooke and Anido, Alejandro Allo and Ibañez-Vega, Jorge and Leslie, Benjamin J and Babu, M Madan and Krenciute, Giedre},
  title = {Computational structural optimization enhances IL13Rα2 – B7-H3 tandem CAR T cells to overcome antigen-heterogeneity-mediated tumor escape},
  journal = {Molecular Therapy},
  year = {2025},
  doi = {10.1016/j.ymthe.2025.07.044}
}
Kostenlos starten →